Literature DB >> 9081549

Pattern of brain morphology in patients with schizophrenia and large cavum septi pellucidi.

P Nopoulos1, V Swayze, N C Andreasen.   

Abstract

Cavum septi pellucidi (CSP) is a midline developmental anomaly shown to have increased incidence in patients with schizophrenia. The etiology of CSP may involve dysgenesis of the temporal lobes. This study evaluated the pattern of brain changes in three groups: 1) normal control subjects, 2) schizophrenic subjects without large CSP, and 3) schizophrenic subjects with large CSP. Patients without large CSP had decreased total brain, frontal, and temporal lobe volumes; patients with the anomaly had more pronounced right > left asymmetry and volume decrement limited to the left temporal lobe. These findings indicate that patients with schizophrenia and large CSP may show a different pattern of disturbed brain morphology than patients without this abnormality.

Entities:  

Mesh:

Year:  1996        PMID: 9081549     DOI: 10.1176/jnp.8.2.147

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  11 in total

Review 1.  MRI anatomy of schizophrenia.

Authors:  R W McCarley; C G Wible; M Frumin; Y Hirayasu; J J Levitt; I A Fischer; M E Shenton
Journal:  Biol Psychiatry       Date:  1999-05-01       Impact factor: 13.382

2.  Amygdala-hippocampal shape differences in schizophrenia: the application of 3D shape models to volumetric MR data.

Authors:  Martha E Shenton; Guido Gerig; Robert W McCarley; Gábor Székely; Ron Kikinis
Journal:  Psychiatry Res       Date:  2002-08-20       Impact factor: 3.222

3.  Volumetric analysis of septal region in schizophrenia and affective disorder.

Authors:  Ralf Brisch; Hans-Gert Bernstein; Dieter Krell; Renate Stauch; Kurt Trübner; Henrik Dobrowolny; Siegfried Kropf; Hendrik Bielau; Bernhard Bogerts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-12-16       Impact factor: 5.270

4.  MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder.

Authors:  J S Kwon; M E Shenton; Y Hirayasu; D F Salisbury; I A Fischer; C C Dickey; D Yurgelun-Todd; M Tohen; R Kikinis; F A Jolesz; R W McCarley
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

5.  Cavum septum pellucidum in schizophrenia: clinical and neuropsychological correlates.

Authors:  Laura A Flashman; Robert M Roth; Heather S Pixley; Howard B Cleavinger; Thomas W McAllister; Robert Vidaver; Andrew J Saykin
Journal:  Psychiatry Res       Date:  2007-02-07       Impact factor: 3.222

Review 6.  A review of MRI findings in schizophrenia.

Authors:  M E Shenton; C C Dickey; M Frumin; R W McCarley
Journal:  Schizophr Res       Date:  2001-04-15       Impact factor: 4.939

7.  Shape of caudate nucleus and its cognitive correlates in neuroleptic-naive schizotypal personality disorder.

Authors:  James J Levitt; Carl Fredrik Westin; Paul G Nestor; Raul S J Estepar; Chandlee C Dickey; Martina M Voglmaier; Larry J Seidman; Ron Kikinis; Ferenc A Jolesz; Robert W McCarley; Martha E Shenton
Journal:  Biol Psychiatry       Date:  2004-01-15       Impact factor: 13.382

8.  Cavum septi pellucidi in first-episode schizophrenia and first-episode affective psychosis: an MRI study.

Authors:  Kiyoto Kasai; Robert W McCarley; Dean F Salisbury; Toshiaki Onitsuka; Susan Demeo; Deborah Yurgelun-Todd; Ron Kikinis; Ferenc A Jolesz; Martha E Shenton
Journal:  Schizophr Res       Date:  2004-11-01       Impact factor: 4.939

9.  The septum pellucidum and its variants. An MRI study.

Authors:  Christine M Born; Eva M Meisenzahl; Thomas Frodl; Thomas Pfluger; Maximilian Reiser; H J Möller; Gerda L Leinsinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-10       Impact factor: 5.270

10.  Predictive potential of cavum septi pellucidi (CSP) in schizophrenics, alcoholics and persons with past head trauma. A post-mortem study.

Authors:  Branislav Filipović; Milan Prostran; Nikola Ilanković; Branka Filipović
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-08       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.